Omixon and AGBL Partner on an Extensive Middle East and North-Africa...
Summary
AGBL will further extend Omixon’s offering to U.A.E, Saudi Arabia, Oman, Turkey, Iran, Uzbekistan, Kyrgyzstan, Tunis, Morocco, Algeria, Egypt, Qatar, Lebanon, Iraq, Syria, Jordan and Armenia through its rich customer database.Omixon’s product offering will allow researchers in the covered geography to explore new frontiers in HLA and ABO typing, though high-performance, high-throughput and high-resolution assays and analysis software.Their commitment to excellence, knowledge of the local HLA typing markets, deep regional coverage, extensive technical support and implementing NGS for HLA in clinical labs will certainly strengthen our global presence and increase the level of expertise in NGS,” commented Marcello Scala, VP Sales, EMEA & Asia, Omixon.Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories.The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region.
Classifications
AskAI Classifications
LabelsLinked Companies
